10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA
Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Annual Report to Security Holders
Earnings Release
News
Announces Pricing of Upsized $90.0 Million Public Offering
Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis (RRMS)
Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership